Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.
Tyler
Kenneth L
KL
Department of Neurology, University of Colorado Health Sciences Center and Denver Veterans Affairs Medical Center, Denver, CO, USA.
Khalili
Kamel
K
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000276:immunology / Q000494:pharmacology; D015967:Gene Expression Regulation, Viral / Q000235:genetics; D006801:Humans; D007577:JC Virus / Q000235:genetics / Q000276:immunology*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000276:immunology* / Q000821:virology*; D009103:Multiple Sclerosis / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology; D000069442:Natalizumab; D014779:Virus Replication / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069442:Natalizumab